Tikva Allocell

$8.0M Series A

Announced: Jul 23, 2026
Sector: biotechnology
Investors: 1

Summary

Tikva Allocell announced an $8 million Series A to advance its lead cell therapy candidate into human clinical trials. The company plans to use the proceeds for IND-enabling studies and a planned IND submission by the end of 2026.

Investors

Kantharos Capital